The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia

Shigeru Kohno; Katsunori Yanagihara; Atsushi Saito; Masao Tateyama; Toshiharu Matsushima; Yoshihito Niki; Akira Watanabe; Kazunori Tomono; Nobuki Aoki; Hiromoto Shintani; Koichi Nishi; Yasuyuki Sano; Naohito Suzuki; Hiroshi Sugiura; Shigetoshi Sakai; Kazuhiro Iizuka; Takashi Ida; Hiroshi Hayakawa; Ikko Hashizume; Akio Tachibana; Ken Ichi Arita; Niro Okimoto; Tadashi Ishida; Shin Kawahara; Atsuhiko Tada; Takeshi Tanimukai; Masatoshi Watanabe; Hirohide Yoneyama; Yukio Matsumoto; Yoshiro Sawae; Masaaki Fukuda; Koji Hashiguchi; Sumio Kawamura; Osamu Sakito; Yuuichi Inoue; Kin Ichi Izumikawa; Kiyoyasu Fukushima; Katsumasa Tokunaga; Yasutsugu Fukuda; Atsushi Maeda; Shun Ichi Kinjo; Mitsuhiko Futenma; Hajime Ohshiro; Yuuei Irabu; Masato Azuma; Taiichi Ohyama; Norifumi Kudeken

The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia

Shigeru Kohno, Katsunori Yanagihara, Atsushi Saito, Masao Tateyama, Toshiharu Matsushima, Yoshihito Niki, Akira Watanabe, Kazunori Tomono, Nobuki Aoki, Hiromoto Shintani, Koichi Nishi, Yasuyuki Sano, Naohito Suzuki, Hiroshi Sugiura, Shigetoshi Sakai, Kazuhiro Iizuka, Takashi Ida, Hiroshi Hayakawa, Ikko Hashizume, Akio TachibanaKen Ichi Arita, Niro Okimoto, Tadashi Ishida, Shin Kawahara, Atsuhiko Tada, Takeshi Tanimukai, Masatoshi Watanabe, Hirohide Yoneyama, Yukio Matsumoto, Yoshiro Sawae, Masaaki Fukuda, Koji Hashiguchi, Sumio Kawamura, Osamu Sakito, Yuuichi Inoue, Kin Ichi Izumikawa, Kiyoyasu Fukushima, Katsumasa Tokunaga, Yasutsugu Fukuda, Atsushi Maeda, Shun Ichi Kinjo, Mitsuhiko Futenma, Hajime Ohshiro, Yuuei Irabu, Masato Azuma, Taiichi Ohyama, Norifumi Kudeken

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

According to the "Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults" (hereinafter referred to as "the community-acquired pneumonia guidelines"), fluoroquinolones, such as tosufloxacin tosilate (TFLX) and sparfloxacin (SPFX), are recommended when Streptococcus pneumoniae (S. pneumoniae) is detected. Few clinical studies have been performed, however, of the efficacy and other characteristics of these antimicrobials. This study examined the efficacy of the fluoroquinolone TFLX against S. pneumoniae-related pneumonia with reference to the community-acquired pneumonia guidelines. This study included pneumonia patients where the presence of S. pneumoniae was suspected by smear staining (smear staining-positive patients) and, of these positive patients, where S. pneumoniae was actually detected (S. pneumoniae-detected patients). There was no difference in background characteristics between 68 smear staining-positive patients and 36 S. pneumoniae-detected patients. The efficacy rate was 92.6% (25/27 patients) at a daily dose of 450 mg (450-mg group) and 100% (35/35 patients) at 600 mg (600-mg group) in the smear staining-positive patients. The two non-responders at 450 mg had moderate pneumonia. In S. pneumoniae-detected patients, the efficacy rate was 93.6% (15/16 patients) in the 450-mg group and 100% (16/16 patients) in the 600-mg group. S. pneumoniae disappeared in 94.1% (16/17 patients) in the 450-mg group and 93.8% (15/16 patients) in the 600-mg group. Against S. pneumoniae isolated in this study, MIC₉₀ of TFLX was 0.25 μg/mL. Based on the daily AUC from TFLX concentration in blood from healthy adults, the AUC/MIC ratio was 46.4 in the 450-mg dose and 62.0 in the 600-mg dose. TFLX was effective against S. pneumoniae-related pneumonia in terms of basic aspects of clinical, antimicrobial and pharmacokinetic properties, showing that TFLX is a respiratory quinolone. In patients with S. pneumoniae-related pneumonia, TFLX should be administered to patients with mild and moderate pneumonia at a daily dose of 450 or 600 mg. The higher dose of 600 mg is probably preferable in moderate cases with more potent inflammatory responses according to clinical symptoms and laboratory findings.

Original language	English
Pages (from-to)	11-19
Number of pages	9
Journal	Japanese Journal of Chemotherapy
Volume	53
Issue number	1
Publication status	Published - 2005 Jan
Externally published	Yes

Keywords

Community-acquired pneumonia
Post marketing surveillance
Streptococcus pneumoniae
TFLX
Tosufloxacin tosilate

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Cite this

Kohno, S., Yanagihara, K., Saito, A., Tateyama, M., Matsushima, T., Niki, Y., Watanabe, A., Tomono, K., Aoki, N., Shintani, H., Nishi, K., Sano, Y., Suzuki, N., Sugiura, H., Sakai, S., Iizuka, K., Ida, T., Hayakawa, H., Hashizume, I., ... Kudeken, N. (2005). The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia. Japanese Journal of Chemotherapy, 53(1), 11-19.

Kohno, S, Yanagihara, K, Saito, A, Tateyama, M, Matsushima, T, Niki, Y, Watanabe, A, Tomono, K, Aoki, N, Shintani, H, Nishi, K, Sano, Y, Suzuki, N, Sugiura, H, Sakai, S, Iizuka, K, Ida, T, Hayakawa, H, Hashizume, I, Tachibana, A, Arita, KI, Okimoto, N, Ishida, T, Kawahara, S, Tada, A, Tanimukai, T, Watanabe, M, Yoneyama, H, Matsumoto, Y, Sawae, Y, Fukuda, M, Hashiguchi, K, Kawamura, S, Sakito, O, Inoue, Y, Izumikawa, KI, Fukushima, K, Tokunaga, K, Fukuda, Y, Maeda, A, Kinjo, SI, Futenma, M, Ohshiro, H, Irabu, Y, Azuma, M, Ohyama, T & Kudeken, N 2005, 'The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia', Japanese Journal of Chemotherapy, vol. 53, no. 1, pp. 11-19.

@article{0b6b57ca9aa046119f56e0e71b3d2a72,

title = "The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia",

abstract = "According to the {"}Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults{"} (hereinafter referred to as {"}the community-acquired pneumonia guidelines{"}), fluoroquinolones, such as tosufloxacin tosilate (TFLX) and sparfloxacin (SPFX), are recommended when Streptococcus pneumoniae (S. pneumoniae) is detected. Few clinical studies have been performed, however, of the efficacy and other characteristics of these antimicrobials. This study examined the efficacy of the fluoroquinolone TFLX against S. pneumoniae-related pneumonia with reference to the community-acquired pneumonia guidelines. This study included pneumonia patients where the presence of S. pneumoniae was suspected by smear staining (smear staining-positive patients) and, of these positive patients, where S. pneumoniae was actually detected (S. pneumoniae-detected patients). There was no difference in background characteristics between 68 smear staining-positive patients and 36 S. pneumoniae-detected patients. The efficacy rate was 92.6% (25/27 patients) at a daily dose of 450 mg (450-mg group) and 100% (35/35 patients) at 600 mg (600-mg group) in the smear staining-positive patients. The two non-responders at 450 mg had moderate pneumonia. In S. pneumoniae-detected patients, the efficacy rate was 93.6% (15/16 patients) in the 450-mg group and 100% (16/16 patients) in the 600-mg group. S. pneumoniae disappeared in 94.1% (16/17 patients) in the 450-mg group and 93.8% (15/16 patients) in the 600-mg group. Against S. pneumoniae isolated in this study, MIC90 of TFLX was 0.25 μg/mL. Based on the daily AUC from TFLX concentration in blood from healthy adults, the AUC/MIC ratio was 46.4 in the 450-mg dose and 62.0 in the 600-mg dose. TFLX was effective against S. pneumoniae-related pneumonia in terms of basic aspects of clinical, antimicrobial and pharmacokinetic properties, showing that TFLX is a respiratory quinolone. In patients with S. pneumoniae-related pneumonia, TFLX should be administered to patients with mild and moderate pneumonia at a daily dose of 450 or 600 mg. The higher dose of 600 mg is probably preferable in moderate cases with more potent inflammatory responses according to clinical symptoms and laboratory findings.",

keywords = "Community-acquired pneumonia, Post marketing surveillance, Streptococcus pneumoniae, TFLX, Tosufloxacin tosilate",

author = "Shigeru Kohno and Katsunori Yanagihara and Atsushi Saito and Masao Tateyama and Toshiharu Matsushima and Yoshihito Niki and Akira Watanabe and Kazunori Tomono and Nobuki Aoki and Hiromoto Shintani and Koichi Nishi and Yasuyuki Sano and Naohito Suzuki and Hiroshi Sugiura and Shigetoshi Sakai and Kazuhiro Iizuka and Takashi Ida and Hiroshi Hayakawa and Ikko Hashizume and Akio Tachibana and Arita, {Ken Ichi} and Niro Okimoto and Tadashi Ishida and Shin Kawahara and Atsuhiko Tada and Takeshi Tanimukai and Masatoshi Watanabe and Hirohide Yoneyama and Yukio Matsumoto and Yoshiro Sawae and Masaaki Fukuda and Koji Hashiguchi and Sumio Kawamura and Osamu Sakito and Yuuichi Inoue and Izumikawa, {Kin Ichi} and Kiyoyasu Fukushima and Katsumasa Tokunaga and Yasutsugu Fukuda and Atsushi Maeda and Kinjo, {Shun Ichi} and Mitsuhiko Futenma and Hajime Ohshiro and Yuuei Irabu and Masato Azuma and Taiichi Ohyama and Norifumi Kudeken",

year = "2005",

month = jan,

language = "English",

volume = "53",

pages = "11--19",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

number = "1",

}

TY - JOUR

T1 - The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia

AU - Kohno, Shigeru

AU - Yanagihara, Katsunori

AU - Saito, Atsushi

AU - Tateyama, Masao

AU - Matsushima, Toshiharu

AU - Niki, Yoshihito

AU - Watanabe, Akira

AU - Tomono, Kazunori

AU - Aoki, Nobuki

AU - Shintani, Hiromoto

AU - Nishi, Koichi

AU - Sano, Yasuyuki

AU - Suzuki, Naohito

AU - Sugiura, Hiroshi

AU - Sakai, Shigetoshi

AU - Iizuka, Kazuhiro

AU - Ida, Takashi

AU - Hayakawa, Hiroshi

AU - Hashizume, Ikko

AU - Tachibana, Akio

AU - Arita, Ken Ichi

AU - Okimoto, Niro

AU - Ishida, Tadashi

AU - Kawahara, Shin

AU - Tada, Atsuhiko

AU - Tanimukai, Takeshi

AU - Watanabe, Masatoshi

AU - Yoneyama, Hirohide

AU - Matsumoto, Yukio

AU - Sawae, Yoshiro

AU - Fukuda, Masaaki

AU - Hashiguchi, Koji

AU - Kawamura, Sumio

AU - Sakito, Osamu

AU - Inoue, Yuuichi

AU - Izumikawa, Kin Ichi

AU - Fukushima, Kiyoyasu

AU - Tokunaga, Katsumasa

AU - Fukuda, Yasutsugu

AU - Maeda, Atsushi

AU - Kinjo, Shun Ichi

AU - Futenma, Mitsuhiko

AU - Ohshiro, Hajime

AU - Irabu, Yuuei

AU - Azuma, Masato

AU - Ohyama, Taiichi

AU - Kudeken, Norifumi

PY - 2005/1

Y1 - 2005/1

N2 - According to the "Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults" (hereinafter referred to as "the community-acquired pneumonia guidelines"), fluoroquinolones, such as tosufloxacin tosilate (TFLX) and sparfloxacin (SPFX), are recommended when Streptococcus pneumoniae (S. pneumoniae) is detected. Few clinical studies have been performed, however, of the efficacy and other characteristics of these antimicrobials. This study examined the efficacy of the fluoroquinolone TFLX against S. pneumoniae-related pneumonia with reference to the community-acquired pneumonia guidelines. This study included pneumonia patients where the presence of S. pneumoniae was suspected by smear staining (smear staining-positive patients) and, of these positive patients, where S. pneumoniae was actually detected (S. pneumoniae-detected patients). There was no difference in background characteristics between 68 smear staining-positive patients and 36 S. pneumoniae-detected patients. The efficacy rate was 92.6% (25/27 patients) at a daily dose of 450 mg (450-mg group) and 100% (35/35 patients) at 600 mg (600-mg group) in the smear staining-positive patients. The two non-responders at 450 mg had moderate pneumonia. In S. pneumoniae-detected patients, the efficacy rate was 93.6% (15/16 patients) in the 450-mg group and 100% (16/16 patients) in the 600-mg group. S. pneumoniae disappeared in 94.1% (16/17 patients) in the 450-mg group and 93.8% (15/16 patients) in the 600-mg group. Against S. pneumoniae isolated in this study, MIC90 of TFLX was 0.25 μg/mL. Based on the daily AUC from TFLX concentration in blood from healthy adults, the AUC/MIC ratio was 46.4 in the 450-mg dose and 62.0 in the 600-mg dose. TFLX was effective against S. pneumoniae-related pneumonia in terms of basic aspects of clinical, antimicrobial and pharmacokinetic properties, showing that TFLX is a respiratory quinolone. In patients with S. pneumoniae-related pneumonia, TFLX should be administered to patients with mild and moderate pneumonia at a daily dose of 450 or 600 mg. The higher dose of 600 mg is probably preferable in moderate cases with more potent inflammatory responses according to clinical symptoms and laboratory findings.

AB - According to the "Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults" (hereinafter referred to as "the community-acquired pneumonia guidelines"), fluoroquinolones, such as tosufloxacin tosilate (TFLX) and sparfloxacin (SPFX), are recommended when Streptococcus pneumoniae (S. pneumoniae) is detected. Few clinical studies have been performed, however, of the efficacy and other characteristics of these antimicrobials. This study examined the efficacy of the fluoroquinolone TFLX against S. pneumoniae-related pneumonia with reference to the community-acquired pneumonia guidelines. This study included pneumonia patients where the presence of S. pneumoniae was suspected by smear staining (smear staining-positive patients) and, of these positive patients, where S. pneumoniae was actually detected (S. pneumoniae-detected patients). There was no difference in background characteristics between 68 smear staining-positive patients and 36 S. pneumoniae-detected patients. The efficacy rate was 92.6% (25/27 patients) at a daily dose of 450 mg (450-mg group) and 100% (35/35 patients) at 600 mg (600-mg group) in the smear staining-positive patients. The two non-responders at 450 mg had moderate pneumonia. In S. pneumoniae-detected patients, the efficacy rate was 93.6% (15/16 patients) in the 450-mg group and 100% (16/16 patients) in the 600-mg group. S. pneumoniae disappeared in 94.1% (16/17 patients) in the 450-mg group and 93.8% (15/16 patients) in the 600-mg group. Against S. pneumoniae isolated in this study, MIC90 of TFLX was 0.25 μg/mL. Based on the daily AUC from TFLX concentration in blood from healthy adults, the AUC/MIC ratio was 46.4 in the 450-mg dose and 62.0 in the 600-mg dose. TFLX was effective against S. pneumoniae-related pneumonia in terms of basic aspects of clinical, antimicrobial and pharmacokinetic properties, showing that TFLX is a respiratory quinolone. In patients with S. pneumoniae-related pneumonia, TFLX should be administered to patients with mild and moderate pneumonia at a daily dose of 450 or 600 mg. The higher dose of 600 mg is probably preferable in moderate cases with more potent inflammatory responses according to clinical symptoms and laboratory findings.

KW - Community-acquired pneumonia

KW - Post marketing surveillance

KW - Streptococcus pneumoniae

KW - TFLX

KW - Tosufloxacin tosilate

UR - http://www.scopus.com/inward/record.url?scp=20044381659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044381659&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:20044381659

SN - 1340-7007

VL - 53

SP - 11

EP - 19

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

IS - 1

ER -

The efficacy of tosufloxacin tosilate against with Streptococcus pneumoniae community-acquired pneumonia

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this